News about "Vanda Pharmaceuticals "

Vanda Pharma's Imsidolimab Gets EU Orphan Designation for Psoriasis

Vanda Pharmaceuticals’ imsidolimab receives European Union (EU) orphan designation for Generalised Pustular Psoriasis (GPP), marking the first such designation for a GPP treatment in the EU.

Vanda Pharmaceuticals | 26/08/2026 | By News Bureau

Vanda Pharmaceuticals Launches NEREUS (tradipitant) for Motion Sickness in US

Vanda Pharmaceuticals launches NEREUS (tradipitant), the first new motion sickness treatment in over 40 years, now available in the US with direct ordering via nereus.us.

Vanda Pharmaceuticals | 04/05/2026 | By News Bureau |  188

Vanda Pharmaceuticals Launches Thetis Study to Test NEREUS for GLP-1 Agonist-Induced Vomiting

Vanda Pharmaceuticals launches Thetis study, a multicenter clinical trial testing NEREUS (oral tradipitant) to prevent vomiting in patients starting high-dose GLP-1 receptor agonists, evaluating safety and efficacy.

Vanda Pharmaceuticals | 09/04/2026 | By News Bureau |  269

Vanda Pharmaceuticals's Imsidolimab BLA Accepted by U.S. Food and Drug Administration for Rare Skin Disease GPP

Vanda’s imsidolimab moves closer to approval as the FDA accepts its BLA for generalised pustular psoriasis, a rare and life-threatening inflammatory skin disorder.

Vanda Pharmaceuticals | 02/03/2026 | By News Bureau |  318

FDA Approves Vanda Pharmaceuticals' BYSANTI as First-Line Therapy for Bipolar I Disorder and Schizophrenia

BYSANTI (milsaperidone), a new atypical antipsychotic from Vanda Pharmaceuticals, gains FDA approval for acute manic or mixed episodes in bipolar I disorder and schizophrenia in adults, with US launch planned for Q3 2026.

Vanda Pharmaceuticals | 21/02/2026 | By News Bureau |  406

Vanda Pharma Wins FDA Approval for NEREUS to Prevent Motion Induced Vomiting

Vanda Pharmaceuticals has received FDA approval for NEREUS (tradipitant) to prevent motion-induced vomiting, marking the first new pharmacologic treatment for motion sickness in more than four decades and a significant advance in managing a condition that affects a large segment of the population and impacts military operational readiness.

Vanda Pharmaceuticals | 31/12/2025 | By News Bureau |  356

FDA Lifts Partial Clinical Hold on Vanda's Tradipitant for Motion Sickness

The lift allows Vanda to extend clinical studies of tradipitant in motion sickness. Meanwhile, the review of the fully completed New Drug Application for tradipitant for the prevention of vomiting induced by motion remains on track.

Vanda Pharmaceuticals | 05/12/2025 | By Dineshwori |  484

Vanda's Tradipitant Shows Strong Efficacy in Preventing Wegovy-Induced Nausea and Vomiting

Vanda Pharmaceuticals has announced positive topline results from its randomised controlled study evaluating tradipitant, an oral neurokinin-1 (NK-1) receptor antagonist, for preventing nausea and vomiting associated with GLP-1 receptor agonist Wegovy in overweight and obese adults.

Vanda Pharmaceuticals | 18/11/2025 | By Dineshwori |  424

Vanda and Anaptys to Develop and Commercialize Imsidolimab

GPP is a rare skin disorder often caused by mutations in the IL36RN gene that codes for a regulatory protein that balances the activity of the proinflammatory IL-36 family of cytokines.

Vanda Pharmaceuticals | 04/02/2025 | By Aishwarya |  612

Vanda Pharmaceuticals Receives Orphan Drug Designation Granted for VGT-1849A

VGT-1849A is a novel ASO treatment candidate for PV and other JAK2-driven hematologic malignancies.

Vanda Pharmaceuticals | 21/12/2024 | By Aishwarya |  1052